- Article
- Source: Campus Sanofi
- 21 May 2025
Welcome to the Payor Portal!
The portal offers you the opportunity to explore the various indications that Sanofi addresses.
This page provides exclusive access to information abou COPD, CSU, and other Type 2 inflammation-related diseases, as well as the treatments Sanofi offers to manage these conditions.
Chronic Obstructive Pulmonary Disease (COPD)
Clincial Burden of COPD
COPD is associated with persistent respiratory symptoms, exacerbations, and inflammation, which contribut...
Economic Burden of COPD in UAE
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung condition characterized by breathing difficulties, with sign...
Proven Efficacy of Dupixent® in COPD
Dupixent® has been approved as the first biologic treatment against COPD
Chronic Spontaneous Urticaria (CSU)
Burdens of CSU
Patients with chronic spontaneous urticaria (CSU) endure a significant and multifaceted burden that wors...
Overall Type 2 Inflammation
Proven Efficacy of Dupixent® against Type 2 Inflammation
Dupixent® has demonstrated significant efficacy in treating various diseases characterized by type 2 inflammation
Proven Safety of Dupixent® against Type 2 Inflammation
Dupixent® has demonstrated a consistent safety profile across multiple Type 2 Inflammation indications
Transplant
cGVHD Burden
Unmet Need
Rezurock Information
Rezurock Efficacy
Rezurock Safety
Economic Benefit